METABOLIC DISORDERS
Parathyroid Hormone effective in fracture prevention in postmenopausal osteoporotic women
Ann Intern Med. 2007 Mar 6;146(5):326-392679 post menopausal women with osteoporosis were randomly assigned to receive either an injection of a parathyroid hormone (PTH), or a placebo, to examine the safety and efficacy of a PTH injection. The results at 18 months, indicated that PTH was successful in reducing the risk for first fracture in those who had no prevalent fracture, as well as reducing additional fracture risk in women who had prevalent fractures. However, the findings of this study also indicated that those treated with PTH had increased hypercalciuria, hypercalcemia, and nausea, compared to the placebo group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
